Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Salix alba bark (white willow bark) is a plant-derived extract from the Salicaceae family used in some over-the-counter products and traditional medicine. Its primary active constituent is salicin—a compound metabolized to salicylic acid in the body—which provides analgesic and anti-inflammatory effects similar to aspirin. Willow bark has been used for centuries to treat pain conditions such as back pain and osteoarthritis; clinical trials have shown moderate efficacy for lower back pain and dysmenorrhea but less so for arthritis. It is not an approved pharmaceutical drug but is available as a dietary supplement or herbal remedy. The mechanism of action involves inhibition of prostaglandin synthesis via cyclooxygenase enzyme blockade due to its conversion into active metabolites[1][2][3][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on salix alba bark.